Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04763200 · ClinicalTrials.gov registry record · NA

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

A NA study of Coronary Artery Disease and Left Ventricular Dysfunction, sponsored by Abiomed.

Active
Registry status
NA
Development phase
1,252
Enrollment target
20
Study locations

NCT04763200: Active NA study of Coronary Artery Disease and Left Ventricular Dysfunction, sponsored by Abiomed.

NCT04763200 is a NA study of Coronary Artery Disease and Left Ventricular Dysfunction that is active but no longer recruiting, run by Abiomed. The registered enrollment target is 1,252 participants, roughly in line with the 1,281-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04763200, a NA study of Coronary Artery Disease and Left Ventricular Dysfunction, is active but no longer recruiting, sponsored by Abiomed.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
1,252 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health after a heart procedure compared to the current standard of care.

Interventions

  • DEVICE Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®
  • DEVICE IABP Intra-aortic balloon pump

Study Locations (20)

California

  • Adventist Health Glendale - Glendale
  • St. Joseph Hospital - Orange - Orange
  • Loma Linda University Health - San Bernardino
  • UCSD Medical Center - San Diego

Illinois

  • Rush University Medical Center - Chicago
  • NorthShore University Health System - Evanston
  • Northwestern University - Evanston
  • Advocate Christ Medical Center - Oak Lawn

Florida

  • The Cardiac & Vascular Institute - Gainesville
  • University of Florida Health - Gainesville - Gainesville
  • UF Health Jacksonville - Jacksonville

Arizona

  • St. Joseph's Medical Center - Phoenix - Phoenix
  • Northwest Medical Center Tucson - Tucson

Georgia

  • Emory University Hospital - Atlanta
  • Northside Cardiovascular Institute - Lawrenceville

Alabama

  • University of Alabama - Birmingham

Arkansas

  • Arkansas Cardiology - Little Rock

Colorado

  • Colorado Heart and Vascular - Lakewood

Trial Details

FieldValue
Enrollment Target 1,252 participants
Start Date 2021-04-13
Est. Completion 2027-10
Phase NA
Abiomed

20 total trials

What the registry record for NCT04763200 still lists

NCT04763200 is an interventional study that assigns participants to a tested intervention. Its 1,252 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,281-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target.

The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Impella CP® / Impella CP® with SmartAssist® / Impella 2.5® is the first listed.

NCT04763200 names 20 study sites across 10 states, led by California, Illinois, Florida.

Frequently Asked Questions

What is clinical trial NCT04763200 about?

NCT04763200 is a clinical study titled "Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function". The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health after a heart procedure compared to the current standard of care.

What is the current status of trial NCT04763200?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,252 participants. The study started on 2021-04-13. Estimated completion is 2027-10.

What conditions does trial NCT04763200 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Left Ventricular Dysfunction.

What interventions are being tested in trial NCT04763200?

The interventions under investigation include: Impella CP® / Impella CP® with SmartAssist® / Impella 2.5® (DEVICE), IABP Intra-aortic balloon pump (DEVICE).

Who is sponsoring clinical trial NCT04763200?

This trial is sponsored by Abiomed, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04763200 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04763200's enrollment target sits among peer trials

1,252 41st of 219 higher than 179 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02743858 · 1,250 participants

    Lymphedema Surveillance Study

  • NCT04670874 · 1,250 participants

    Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29

  • NCT04807868 · 1,250 participants

    AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)

  • NCT05995821 · 1,250 participants

    Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04763200, the US trial registry maintained by the National Library of Medicine. NCT04763200 (large enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.